Drugs / Zirconium Zr 89 Panitumumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05747625 | May 2023 → Feb 2027 expected | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Eben Rosenthal | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zirconium Zr 89 Panitumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747625 ↗ |
| Modality | Diagnostic / imaging agent | “89Zr panitumumab is an investigational imaging agent” NCT05747625 ↗ |
| Route | Intravenous | “Given IV” NCT05747625 ↗ |
| Target | EGFR | “radiolabeled anti-EGFR antibody” NCT05747625 ↗ |